Back to News
Market Impact: 0.38
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Source: Nasdaq
Corporate Guidance & OutlookCorporate EarningsHealthcare & BiotechCompany Fundamentals
Bristol Myers Squibb reported 15% second-quarter sales growth in its Growth Portfolio and raised its 2026 revenue outlook to $49 billion-$50 billion. The upgraded guidance signals improving momentum in the company’s newer product base and is a positive catalyst for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.58
Ticker Sentiment
BMY0.72
More News
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
- Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
- Northern Star shares pop as Australian gold miner rejects $27-billion takeover proposal
- Here are the 4 big things we're watching in the stock market in the week ahead
- Paramount Warner Deal Tests Hollywood’s Future
- Healey pledges “new age of industrialisation” as Government backs British shipbuilding
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle